coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Central & West Warrington PCN, Warrington (LAD) · Health Inequalities Profile

    PCN U96870 · NHS Cheshire and Merseyside Integrated Care Board · 7 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    67,048

    Registered population

    61.8% aged 18–64

    19.1%

    Aged 65+

    ICB 19.0% · England 17.9%

    7.5%

    Ethnic minority (non-White)

    4.0% Asian · England 9.6%

    21.5%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~12,435

    Core20 residents (est.)

    Resident basis; registered basis ~17,288 · see page 3

    11,392

    Hypertension register

    +6.74% in 3 yrs · England +5.60%

    763

    SMI register

    34.3% of Warrington (LAD)'s

    1,350

    COPD register

    Reviews +5.73% in 3 yrs

    Forecast to 2030

    13,063

    Hypertension patients, 2030

    +1,671 on today

    59.0%

    QRISK ≥20% on statins, 2030

    -3.63pp over 3 yrs

    4.6%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    -5.2%
    High-risk lipid therapy fell over three years.

    QRISK ≥ 20% lipid therapy fell 5.2% over 2023 to 2025 (England +6.2%) to 65.7%, which may reflect unverified recall gaps.

    71.0%
    Heart failure functional reviews trail England.

    Annual heart failure functional reviews sit at 71.0% (England 78.5%) after falling 1.6% over 2023 to 2025 against England's +8.7% rise.

    +37.6%
    Asthma review coverage rose sharply since 2023.

    Annual asthma reviews rose +37.6% over 2023 to 2025 (England +4.4%) to 67.7%, though about 1,400 registered patients still lack a recorded review.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ make up 19.1% of the list alongside 32 catchment care homes

    The PCN registers 67,048 patients across seven practices. Of registered patients, 19.1% (12,799 patients) are aged 65+, compared to 17.5% in Warrington (LAD), 19.0% in NHS Cheshire and Merseyside ICB, and 17.9% in England. Projected list growth to 2030 is 0.3% (Warrington (LAD) 0.7%, ICB 2.3%, England 2.3%; methodology unverified). By Census usual resident estimates, 92.5% are White (England 81.1%) and 4.0% are Asian or Asian British (Warrington (LAD) 3.3%, England 9.6%), reaching 8.6% at Dallam Lane Medical Centre.

    Age profile

    0–1719.1%
    18–6461.8%
    65+19.1%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White92.5%
    Asian4.0%
    Mixed1.6%
    Other1.1%
    Black0.9%

    Older people · falls rows are Warrington (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Warrington LA)1,7372,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)83.7%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)58.7%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Warrington LA)9051,0219552024/25
    Falls deaths, all ages, per 100,000 (Warrington LA)12.118.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Deprivation is moderate overall but masks a 53.3 pp practice divide

    Average IMD is decile 6.2 and Core20 prevalence is 21.5%, above Warrington (LAD) (16.9%) and England (21.0%). Across practices, Core20 share spans 53.3 pp, from 53.3% at Dallam Lane Medical Centre to 0.0% at Penketh Health Centre. Estimated Core20 volume is highest at The Eric Moore Partnership (6,363 patients) and Folly Lane Medical Centre (4,743 patients). Practice-weighted registered estimates total 17,288 patients (25.8% share), diverging from 12,435 resident patients in deciles 1 and 2. Different denominator bases require reconciliation before deploying targeted outreach.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Dallam Lane53.3% · 2,704 patients
    Eric Moore50.6% · 6,363 patients
    Folly Lane50.1% · 4,743 patients
    Helsby Street31.7% · 2,709 patients
    Westbrook5.5% · 552 patients
    Causeway2.4% · 217 patients
    Penketh0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    763

    SMI register

    1.12% recorded prevalence

    410

    Learning disability register

    0.60% recorded prevalence

    32

    Care homes, 1,289 beds

    In the PCN catchment

    9.4%

    Provide unpaid care

    Warrington (LAD), Census 2021

    The PCN records 763 patients on the severe mental illness register (1.1% prevalence) and 410 on the learning disability register (0.6%), alongside 32 catchment care homes (1,289 beds). Borough context includes 9 people sleeping rough in the 2025 autumn snapshot and an estimated ceiling of 6,303 unpaid carers (applying the 9.4% borough rate), neither of which represents a registered PCN count.

    Severe mental illness: physical health checks

    Recorded SMI prevalence is 1.1%. Annual checks reached 85.6% for blood pressure and 86.6% for BMI, but three-year blood pressure check growth (+1.1 pp) lagged England (+4.4 pp), which could indicate slowing physical health check momentum.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    11,392

    Hypertension register

    +6.74%

    Register growth, 3 yrs

    Warrington (LAD) +6.41% · England +5.60%

    +1.98pp

    BP control, under 80

    ≤140/90 · +0.05pp aged 80+

    +1,671

    More patients by 2030

    Forecast 13,063 (19.11%)

    Hypertension case-finding and control

    Hypertension register prevalence is 16.8% (11,392 patients), compared to 16.4% in Warrington (LAD), 16.8% in NHS Cheshire and Merseyside Integrated Care Board, and 15.2% in England. Among diagnosed patients, 70.5% are treated to target, which is in line with England (70.3%) and above the borough (68.7%). However, recent blood pressure recording reaches 86.2%, matching the borough (86.2%) but trailing England (90.0%) and the ICB (88.3%), despite a three-year rise of +4.3% (+3.6% in England). Observation periods were not supplied for current prevalence figures. Blood pressure recording trails national levels, which may leave unmonitored hypertensive patients at risk of uncontrolled disease and prioritises systematic annual recall.

    Lipids and statins

    Lipid-lowering therapy coverage for patients with QRISK ≥ 20% is 65.7%, exceeding England (63.6%) and Warrington (LAD) (61.6%). However, coverage fell 5.2% over 2023 to 2025 (England +6.2%). Three-year coverage trails national progress, which could suggest an emerging recall gap to investigate among high-risk patients.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026112,826£1.50£1.71£1.86£169,239
    Cardiovascular (all), 2025155,972£5.37£4.37£3.33£837,570

    For lipid-regulating drugs in 2026, PCN cost per item was £1.50 across 112,826 items, compared to £1.86 in England, £1.59 in Warrington (LAD), and £1.71 in the ICB. This is £40,617 less than at England's unit cost. Spending less than England's unit cost could offer prescribing headroom to prioritise expanding treatment reach to under-served high-risk cohorts.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +37.60%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +3.88%

    Asthma prevalence, PCN 3-yr % change

    Asthma reviews rose +37.6% (+18.5 pp) over 2023 to 2025 to 67.7% (England 65.7%), and COPD reviews reached 77.8% (England 76.4%). However, an estimated 1,382 asthma patients on the 4,280 register remain without a recorded review. Furthermore, recording of second-hand smoke exposure among asthma patients aged 6–19 stands at 75.8% (336 patients), trailing England (78.8%) by 3.0 percentage points. This gap suggests that younger respiratory cohorts may require targeted proactive review outreach.

    Cancer register and children's immunisation

    Recorded cancer prevalence is 3.9% (2,643 patients). For childhood immunisations, 24-month coverage is below the 95% coverage target by 4.9 pp for MMR dose 1 (90.1%) and by 3.5 pp for the 6-in-1 complete primary course (91.5%), with MMR dose 2 coverage at age 5 reaching 94.2%. Across captured practices, the range in QOF vaccination and immunisation-domain achievement is 73.5 pp. Folly Lane Medical Centre recorded 26.53%. Penketh Health Centre recorded 100.0%.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months94.8%

    England 91.0%

    6-in-1 complete primary course at 24 months91.5%

    England 92.2%

    MMR dose 1 at 24 months90.1%

    England 88.3%

    MMR dose 2 at age 594.2%

    England 82.8%

    4-in-1 pre-school booster at age 594.8%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    In 2022, 55.5% of staged cancers across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2 (England 55.3%), sitting below the 75.0% national ambition by 19.5 percentage points. Closing this ICB gap requires about 2,640 extra early-stage diagnoses annually, with early presentation lagging below the ambition by 34.6 percentage points in lung (40.4%) and 30.1 percentage points in bowel (44.9%). In the PCN, 2,643 patients are on the cancer register (3.9%). Cervical screening coverage aged 25–49 is 70.5% overall, falling to 64.2% at Dallam Lane Medical Centre. Proactive screening recall in lower-coverage practices could help address local uptake variation.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026 (provisional), North Cheshire and Mersey NHS Foundation Trust achieved 83.7% against the 85.0% cancer 62-day referral to treatment standard, below the standard by 1.3 percentage points. It exceeded Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), Manchester University NHS Foundation Trust (72.8%), NHS Cheshire and Merseyside Integrated Care Board (76.2%), and England (71.2%). The trust reached 80.2% on the 28-day faster diagnosis standard, exceeding the 75.0% standard, ahead of the ICB (77.2%) and England (79.3%). These metrics reflect trust rather than PCN performance.

    Pathways within standard (%)North Cheshire and MerseyMersey and West LancashireManchesterCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)80.2172.3980.0677.2579.32
    31-day treatment (96%)98.1795.4692.5495.7192.50
    62-day referral to treatment (85%)83.6777.9672.8576.2371.16
    Diagnostic waits over 6 weeks (%)North Cheshire and MerseyMersey and West LancashireManchesterEngland
    MRI0.5314.0411.6821.40
    CT2.3213.0814.669.92
    Echocardiography28.0434.884.9128.48
    Colonoscopy15.9818.044.5130.83
    Gastroscopy20.2418.1729.3529.02
    All 15 DM01 tests6.3421.178.9823.14
    Community services activityWarrington residentsCheshire and Merseyside ICB
    Care contacts38,550541,280
    Referrals7,32097,150
    Patients with a contact14,830146,240

    Community services (residents of Warrington), Jun 2026 (provisional). In June 2026 (provisional), Warrington borough residents accounted for 38,550 community service contacts. Adults aged 65 and over represented 56% of these contacts (21,595 contacts). These borough-level data reflect local demand for community services rather than PCN-level delivery.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Eric Moore11350.667.4%73.1%82.3%
    Causeway932.470.9%63.6%77.3%
    Penketh1040.044.1%70.5%77.2%
    Dallam Lane9653.378.9%87.8%76.5%
    Helsby Street10831.744.7%65.6%73.5%
    Folly Lane9350.131.3%66.4%70.2%
    Westbrook1065.540.6%73.2%67.8%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNWarrington (LAD)AssetPCNWarrington (LAD)
    Care homes (catchment)32 (1,289 beds)n/aSchools (catchment)99n/a
    Children's centres712Places of worship4989
    Libraries27Primary schools (LA maintained)1728
    Primary academies1731Special schoolsn/a1

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Heart failure register and review recall

    Heart failure prevalence is 1.0% (699 patients vs Warrington (LAD) 1.1%, England 1.1%; modelled gap +37 to +68), while functional reviews (71.0% vs England 78.5%) fell 1.6% over 2023 to 2025 (England +8.7%). For discussion: run structured recall for annual functional assessments and audit records for uncoded heart failure. Moderate effort to run.

    Option 2

    Asthma review and youth smoke recall

    Despite +37.6% growth to 67.7% (England 65.7%), an estimated 1,382 of 4,280 asthma patients lack a recorded review, and youth second-hand smoke recording is 75.8% (England 78.8%). For discussion: offer flexible review slots and check templates prompt second-hand smoke recording for ages 6 to 19. Low cost, quick to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 3

    CVD lipid therapy and BP recall

    QRISK ≥ 20% lipid therapy (65.7%) fell 5.2% (-3.6 pp; England +6.2%), recent BP checks (86.2%) trail England (90.0%), and 2025 CVD drug cost (£5.37) is £318,183 more than England's (£3.33) across 155,972 items. For discussion: run pharmacist-led lipid recall alongside annual BP checks for the 11,392 hypertension register. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Culturally adapted access review (p2)Asian / Asian BritishNeighbourhood health framework · Core20PLUS5 approachPCN
    Core20 list reconciliation and outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check recall audit (p4)Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension blood pressure recall audit (p5)Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Childhood immunisation recall review (p6)MMR dose 1 coverage at 24 months10YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026Practice
    Option 1 · Heart failure register and review recall (p12)Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs)—PCN
    Option 2 · Asthma review and youth smoke recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 3 · CVD lipid therapy and BP recall (p12)Hypertension register · Hypertension patients with a recent BP reading · Patients with QRISK ≥ 20% treated with lipid lowering therapyCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15